Reinforcing Odimma’s Position Within France’s Leading Oncology Innovation Ecosystem.
Odimma Therapeutics has been selected as one of the successful applicants supported by the Paris Saclay Cancer Cluster (PSCC), joining a new group of innovative oncology projects recognized for their scientific ambition and transformative potential.
This selection represents an important milestone for Odimma Therapeutics as the company continues advancing ODI-2001, its next-generation personalized immunotherapy platform combining AI-driven neoantigen selection and synthetic DNA technologies.
The Paris Saclay Cancer Cluster is one of France’s leading oncology innovation ecosystems, designed to accelerate breakthrough healthcare initiatives by providing selected companies with access to expertise, infrastructure, scientific resources and strategic support.
By integrating cutting-edge technologies and pioneering approaches in precision oncology, Odimma Therapeutics aims to contribute to the future of personalized cancer treatment and next-generation immunotherapy development.
“We are thrilled to be selected by the Paris Saclay Cancer Cluster. This recognition reflects both the scientific ambition of the Odimma platform and our commitment to addressing major public health challenges through innovation in personalized immunotherapy.”
The November 2024 PSCC selection includes ten new oncology-focused projects leveraging advanced technologies across artificial intelligence, immunotherapy, molecular engineering, diagnostics and targeted therapeutics.
Among the selected companies, Odimma Therapeutics was recognized for its work developing personalized immunotherapies powered by AI and synthetic DNA technologies.
The company is proud to join this community of innovators working to accelerate transformative advancements in oncology and healthcare.
